Frankfurt - Delayed Quote EUR

Bristol-Myers Squibb Company (BRM.F)

42.57

-0.22

(-0.53%)

As of 11:47:48 AM GMT+2. Market Open.

Bristol Myers: Q1 Earnings Snapshot

PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported first-quarter net income of $2.46 billion, after reporting a loss in the same period a year earlier. The Princeton, New Jersey-based company said it had profit of $1.20 per share. Earnings, adjusted for amortization costs and non-recurring costs, came to $1.80 per share.

Associated Press Finance 38 minutes ago

CELG-RT
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales

(Reuters) -Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer. The company's shares have dropped more than 20% over the past month as investor concerns about U.S. President Donald Trump's tariff threats have roiled the markets. Chief Financial Officer David Elkins said in an interview that the company's global manufacturing footprint puts it in a good position to deal with whatever tariffs may come.

Reuters 47 minutes ago

CELG-RT
Bristol Myers Squibb Reports First Quarter Financial Results for 2025

PRINCETON, N.J., April 24, 2025--Bristol Myers Squibb Reports First Quarter Financial Results for 2025

Business Wire 51 minutes ago

BMY

CELG-RT
These Stocks Moved the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More

Tesla stock rises as CEO Elon Musk says in May he’ll be cutting back ’significantly’ his work with the Trump administration’s Department of Government Efficiency.

Barrons.com 15 hours ago

BA

ENPH

TSLA
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.

Zacks 19 hours ago

REGN

CELG-RT
Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook

Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.

Barrons.com 21 hours ago

CELG-RT
Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over […]

Insider Monkey 21 hours ago

CELG-RT
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsycho

Benzinga 21 hours ago

CELG-RT
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.

Zacks 22 hours ago

ABBV

SNY

CELG-RT
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know.

StockStory 23 hours ago

CELG-RT
BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment

The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.

Clinical Trials Arena yesterday

CELG-RT
Bristol Myers’ prized schizophrenia drug stumbles in testing

A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.

BioPharma Dive yesterday

CELG-RT
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

PRINCETON, N.J., April 22, 2025--BMS Announces Topline Results from Phase 3 ARISE Trial

Business Wire yesterday

BMY

CELG-RT
Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test

Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.

Investor's Business Daily yesterday

BMY

CELG-RT
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

NEO

CELG-RT
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks yesterday

CELG-RT
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.

Zacks yesterday

ABBV

CELG-RT

SNY
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 billion acquisition of MyoKardia for its obstructive hypertrophic myopathy (HCM) drug, Camzyos, in 2020, the pharmaceutical giant has had difficulty achieving a return on investment. Bristol once believed Camzyos, FDA-approved for obstructive HCM (oHCM), could generate $4 billion in peak annual sales, but this has taken a hit on many fronts. Last week, Bristol revealed th

TipRanks yesterday

BMY

CELG-RT

CYTK
Bristol Myers says FDA updates Camzyos label to simplify treatment

Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility by reducing contraindications. “In addition to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clin

TipRanks 5 days ago

BMY

CELG-RT
Bristol-Myers Squibb (NYSE:BMY) Gains FDA Approval To Simplify Camzyos Monitoring Process

Bristol-Myers Squibb (NYSE:BMY) recently announced an update from the FDA on CAMZYOS®, focusing on simplified treatment protocols and expanded patient eligibility, as well as an FDA approval for its Opdivo® and Yervoy® combination for specific cancer treatments. Despite these positive regulatory advances, the company's stock experienced a 2.44% decline over the past week. This move contrasts with a generally flat market trend during the same period. The mixed results from the ODYSSEY-HCM...

Simply Wall St. 5 days ago

BMY

CELG-RT

Performance Overview

Return	BRM.F	S&P 500 (^GSPC)
YTD	-20.59%	-8.60%
1-Year	-1.52%	+6.00%
3-Year	-31.85%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bristol-Myers Squibb Company (BRM.F)

Bristol Myers: Q1 Earnings Snapshot

Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales

Bristol Myers Squibb Reports First Quarter Financial Results for 2025

These Stocks Moved the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook

Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect

BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment

Bristol Myers’ prized schizophrenia drug stumbles in testing

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

Bristol Myers says FDA updates Camzyos label to simplify treatment

Bristol-Myers Squibb (NYSE:BMY) Gains FDA Approval To Simplify Camzyos Monitoring Process

Performance Overview